Deferiprone

• Description:

  Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study[1][2][3][4][5][6][7][8].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Apoptosis; COX; Ferroptosis; HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Endocrinology; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Deferiprone.html

• Purity:

  99.98

• Solubility:

  DMSO : 7.14 mg/mL (ultrasonic) |H2O : 3.33 mg/mL (ultrasonic)

• Smiles:

  O=C1C(O)=C(C)N(C)C=C1

• Molecular Formula:

  C7H9NO2

• Molecular Weight:

  139.15

• Precautions:

  H302

• References & Citations:

  [1]Kontoghiorghes GJ, et al. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003;26 (8) :553-584.|[2]Rui V. Simões, Inhibition of prostate cancer proliferation by Deferiprone. NMR Biomed|[3]Oded Shalev. et al. Deferiprone (L1) Chelates Pathologic Iron Deposits From Membranes of Intact Thalassemic and Sickle Red Blood Cells Both In Vitro and In Vivo.|[4]Ngan Thi Tran, et al. Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition. Platelets 2020 May 18;31 (4) :505-512. |[5]Andrea Pagani, MD, et al. Deferiprone Stimulates Aged Dermal Fibroblasts via HIF-1α Modulation.Pathog Dis. 2018 Jul 1;76 (5) .|[6]Débora C Coraça-Huber, et al. Iron chelation destabilizes bacterial biofilms and potentiates the antimicrobial activity of antibiotics against coagulase-negative Staphylococci. Pathogens and Disease, Volume 76, Issue 5, July 2018, fty052|[7]Shalini S. Rao, et al. Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology. Neurotherapeutics. 2021 Apr;18 (2) :1081-1094.|[8]Makhdoumi P, et al. Oral deferiprone administration ameliorates cisplatin-induced nephrotoxicity in rats.J Pharm Pharmacol. 2018 Oct;70 (10) :1357-1368. |[9]Yanan Zhang, et al. Taurine and deferiprone against Al-linked apoptosis in rat hippocampus. J Trace Elem Med Biol. 2023 Mar;76:127113.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [30652-11-0]